Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$136.39|
|52 Week High||US$82.88|
|52 Week Low||US$142.64|
|1 Month Change||5.04%|
|3 Month Change||24.96%|
|1 Year Change||62.16%|
|3 Year Change||201.02%|
|5 Year Change||428.03%|
|Change since IPO||582.29%|
Recent News & Updates
|CTLT||US Pharmaceuticals||US Market|
Return vs Industry: CTLT exceeded the US Pharmaceuticals industry which returned 14.3% over the past year.
Return vs Market: CTLT exceeded the US Market which returned 35.3% over the past year.
Stable Share Price: CTLT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: CTLT's weekly volatility (3%) has been stable over the past year.
About the Company
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Catalent Fundamentals Summary
|CTLT fundamental statistics|
Is CTLT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CTLT income statement (TTM)|
|Cost of Revenue||US$2.65b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||3.10|
|Net Profit Margin||13.23%|
How did CTLT perform over the long term?See historical performance and comparison
Is Catalent undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CTLT ($141.34) is trading above our estimate of fair value ($130.35)
Significantly Below Fair Value: CTLT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CTLT is poor value based on its PE Ratio (45.7x) compared to the US Pharmaceuticals industry average (22x).
PE vs Market: CTLT is poor value based on its PE Ratio (45.7x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: CTLT is poor value based on its PEG Ratio (3.8x)
Price to Book Ratio
PB vs Industry: CTLT is overvalued based on its PB Ratio (6.2x) compared to the US Pharmaceuticals industry average (3.2x).
How is Catalent forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTLT's forecast earnings growth (12% per year) is above the savings rate (2%).
Earnings vs Market: CTLT's earnings (12% per year) are forecast to grow slower than the US market (15% per year).
High Growth Earnings: CTLT's earnings are forecast to grow, but not significantly.
Revenue vs Market: CTLT's revenue (9.1% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: CTLT's revenue (9.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CTLT's Return on Equity is forecast to be low in 3 years time (13.8%).
How has Catalent performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTLT has a large one-off gain of $145.0M impacting its June 30 2021 financial results.
Growing Profit Margin: CTLT's current net profit margins (13.2%) are higher than last year (5.6%).
Past Earnings Growth Analysis
Earnings Trend: CTLT's earnings have grown significantly by 35.8% per year over the past 5 years.
Accelerating Growth: CTLT's earnings growth over the past year (205.8%) exceeds its 5-year average (35.8% per year).
Earnings vs Industry: CTLT earnings growth over the past year (205.8%) exceeded the Pharmaceuticals industry 17.5%.
Return on Equity
High ROE: CTLT's Return on Equity (13.7%) is considered low.
How is Catalent's financial position?
Financial Position Analysis
Short Term Liabilities: CTLT's short term assets ($2.9B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: CTLT's short term assets ($2.9B) do not cover its long term liabilities ($3.6B).
Debt to Equity History and Analysis
Debt Level: CTLT's debt to equity ratio (71.4%) is considered high.
Reducing Debt: CTLT's debt to equity ratio has reduced from 282.6% to 71.4% over the past 5 years.
Debt Coverage: CTLT's debt is not well covered by operating cash flow (14.2%).
Interest Coverage: CTLT's interest payments on its debt are well covered by EBIT (6x coverage).
What is Catalent current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTLT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTLT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Chiminski (57 yo)
Mr. John R. Chiminski serves as Independent Director at Berkeley Lights, Inc. since May 14, 2021. Mr. Chiminski has been the Chief Executive Officer at Catalent, Inc. since March 2009 and has been its Chai...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD12.58M) is about average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.
Experienced Management: CTLT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: CTLT's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.
Catalent, Inc.'s employee growth, exchange listings and data sources
- Name: Catalent, Inc.
- Ticker: CTLT
- Exchange: NYSE
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$23.304b
- Shares outstanding: 170.86m
- Website: https://www.catalent.com
Number of Employees
- Catalent, Inc.
- 14 Schoolhouse Road
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 23:04|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.